Flea Control Products Research Articles

Fipronil and (S)-methoprene can lessen the risk of transmission of Bartonella clarridgeiae among cats with exposure to Ctenocephalides felis.

To cohouse cats experimentally infected with Bartonella clarridgeiae (Bc) with naive cats in a flea-free environment or with Ctenocephalides felis, Bartonella henselae (Bh), Mycoplasma haemofelis, and Candidatus Mycoplasma haemominutum to determine which flea could be a vector and to assess whether transmission of the infectious agents could be blocked by fipronil and (S)-methoprene. Specific pathogen-free cats (n = 34). In experiment 1, Bc was inoculated in 1 cat that was housed with 9 naive cats without C felis. In experiment 2, the 2 cats inoculated with Bc were housed with 6 other cats (2 inoculated with Bh, 2 inoculated with M haemofelis, and 2 inoculated with Candidatus M haemominutum) in the center (enclosure 2) of 3 housing enclosures separated by mesh walls that allow passage of fleas but precludes fighting. C felis were placed only on cats in enclosure 2 (5 times). Cats in enclosures 1 (n = 8) and 2 (8) were untreated, and cats in enclosure 3 (8) were administered fipronil and (S)-methoprene. Blood was collected from all cats for PCR assays for the pathogens. None of the cats housed with the cat inoculated with Bc became PCR positive in the absence of C felis. All cats in enclosure 2 became Bc DNA positive. While 2 of 8 cats in enclosure 1 became Bc PCR positive, none of the treated cats in enclosure 3 became infected. The study demonstrated that C felis can be a vector for Bc. The results support the recommendation that flea control products can reduce the risk of transmission of flea-borne pathogens.

A Dietary Plant Extract Formulation Helps Reduce Flea Populations in Cats: A Double-Blind Randomized Study.

There is a growing demand for natural products to be used to control fleas in pets. A prospective, double-blind, randomized, placebo-controlled study evaluated the efficacy of the biological plant-based food supplement Bioticks® (thyme, rosemary, lemon balm, fenugreek, wormwood, and lemongrass extracts) as a flea control product in naturally flea-infested cats with an indoor-outdoor lifestyle. Ten cats were used as placebo controls (group A). Ten other cats were fed the same daily diet but supplemented with Bioticks® (group B). Fleas were counted by combing at D0 and D0 + 14 days, then one, two, three, four, and five months after the start of this study. No flea treatment was administered, and no environmental changes were made for six months prior to the start and throughout this study. The product was well-tolerated. The mean flea population in group B progressively and steadily decreased to reach 3.3 ± 2.1 at month five. At the same time and under similar maintenance conditions, the average flea population in group A remained stable (14.3 ± 2.5) until the fifth month. The percentages of efficacy (Abbott formula) in group B compared to group A was 27%, 20%, 52%, 66%, and 77%, respectively, at one, two, three, four, and five months after the start of this study.

Evaluation of a topical sarolaner-selamectin combination to control flea populations on naturally infested cats in private residences in West Central Florida

Historic data show that home flea infestations can be managed by treating all animals on the premises with a highly effective flea control product. The use of effective products has also been shown to reduce pruritus and minimize dermatologic lesions in both cats and dogs. Therefore, an in-home study was conducted in West Central Florida USA to evaluate the efficacy of a topically applied selamectin-sarolaner formulation to control fleas in naturally infested cats over a 12-week period. Thirty-seven cats in 21 households were treated once monthly with the selamectin-sarolaner topical solution. In the topical fluralaner treatment (positive control) group, forty-three cats in 20 households were treated once on day 0. A combined total of thirty dogs in both groups were treated once monthly with oral sarolaner. Fleas on cats were counted by flea combing, fleas on dogs were counted using visual area counts and fleas in the indoor premises were assessed using intermittent-light flea traps. Blinded-assessments of feline dermatologic lesions (modified-SCORFAD) were conducted monthly by a boarded-dermatologist and pruritus severity was evaluated by pet owners. Three consecutive monthly treatments of selamectin-sarolaner reduced flea populations on cats by 96.3 % within 7 days and by 100% from week 6 to the end of the 12-week study. The topical application of fluralaner reduced flea populations by 98.1 % within 7 days and efficacy reached 100% by week 12. At the end of the study, fleas were completely eradicated (from cats, dogs and homes) in every home regardless of treatment group. Owner reported cat pruritus was reduced by > 87 % in both treatment groups by week 12. Significant improvements in dermatologic lesion scores (> 81 %) were achieved by both products by the end of the study. Monthly applications of topical selamectin-sarolaner or topical fluralaner to cats living in the heavy flea challenge environment of West Central Florida USA were effective in eradicating flea infestations, reducing pruritus and improving dermatologic lesions.

Evaluation of a plant-based food supplement to control flea populations in dogs: A prospective double-blind randomized study

A prospective double-blind randomized placebo-controlled study evaluated the tolerance and efficacy of the biological plant-based food supplement Bioticks® (extracts of thyme, rosemary, melissa, fenugreek, absinthe and lemongrass) as a flea-control product. Twelve dogs were used as placebo controls (group A). Ten dogs under similar housing conditions received the same food daily but supplemented with Bioticks® (group B). Flea counts were performed on D0 and 14, then 1, 2, 3, 4 and 5 months after the beginning of the study. No flea treatment was given or environmental modifications made during the 6 months prior to beginning and throughout the duration of the study. Efficacy was calculated according to Abbott's formula. No adverse event was recorded. At inclusion, dogs in groups A and B hosted a mean ± standard deviation of 7.9 ± 3.3 and 9.5 ± 3.6 fleas, respectively. The mean flea population in group A steadily increased until 4 months after D0 (21.5 ± 4.9 fleas/dog). Meanwhile, the mean flea population in group B dogs remained stable for the first month but then steadily decreased to reach an average of 3.1 ± 1.7 fleas/dog at D0+5 months. The percentage efficacy in the treated group as compared to the non-treated group was 33%, 51%, 71%, 80% and 82% at 1, 2, 3, 4 and 5 months, respectively.Bioticks® was shown to be safe and effectively limited the flea population in dogs with a moderate flea infestation in conditions that were highly favourable to flea development. This is the first study to evaluate a plant-based product as an oral supplement for flea control.

Canine flea control: too much choice?

Ectoparasite control forms an important part of any routine canine health programme but is also an integral part of the management of pruritic skin disease in the dog. As such it is important that veterinary surgeons are aware of the life cycle of the flea and the mode of action of the numerous flea control products that are currently available. The suitability of a product may be different depending on the health status of the dog and concurrent therapy. This article considers the most important groups of flea control products.

In-home assessment of flea control and dermatologic lesions in dogs provided by lotilaner (Credelio®) and spinosad (Comfortis®) in west central Florida

Post-launch field investigations of recently-approved flea control products establish an efficacy baseline and in subsequent years can detect any efficacy decline suggestive of emerging resistance. As part of a continuing program of yearly assessment of flea control products in west central Florida, this study, using client-owned dogs, investigated the efficacy of lotilaner and spinosad in controlling fleas and in alleviating dermatologic signs likely associated with flea infestations. Forty-four qualifying households were randomized to either a lotilaner (Credelio®) (minimum dose rate 20 mg/kg) or a spinosad (Comfortis®) (30 mg/kg) group, with 33 and 36 dogs in each group, respectively. On Days 0 and 28 (±2) all dogs in each household were treated with the allocated product according to label directions, and all household cats received spinetoram (Cheristin®). On Day 0 and at weekly intervals through Day 56 (±2), on-animal and premises flea burdens were enumerated, a veterinary dermatologist scored integumental changes using canine atopic dermatitis extent and severity index (CADESI)-4 and flea allergy dermatitis (FAD) scales, and owners scored pruritus using the validated canine pruritus severity scale (CPSS).At study entry geometric mean flea counts were 33.2 and 29.9 in the lotilaner and spinosad groups, respectively. For both groups, reductions in flea counts were > 99% at the first post-treatment assessment (Week 1), and 100% from Week 6 through the final assessment (Week 8) when all study dogs were flea-free. For both groups, at each timepoint, flea counts on dogs and in traps were significantly reduced compared to the initial assessment (p < 0.001), as were improvements in median CADESI-4, FAD and CPSS scores (p ≤ 0.001). At Week 4, the geometric mean flea count on dogs in the lotilaner group (0.1) was significantly lower than that of dogs in the spinosad group (0.6) (p = 0.027), significantly fewer dogs in the lotilaner group were found to have fleas (p = 0.034), and mean owner-rated pruritus scores were significantly lower (p = 0.025).Under field conditions favoring heavy flea challenge, two consecutive monthly treatments of dogs with either lotilaner or spinosad produced a 100% reduction in canine flea infestations and dramatic improvements in dermatologic lesions and pruritus, based on scoring by a veterinary dermatologist and by dog owners. Household flea burdens were driven to extinction in all but one home in each treatment group.

Comparative Efficacy of Three Commercial Ectoparasiticides against Fleas in Naturally Infested Dogs

Fleas that infest pets are considered important parasites of both animals and humans. These insects cause irritation and can also transmit zoonotic diseases. Research has led to a rapid expansion in the development of flea control products. In the face of a market that offers dozens of commercial ectoparasiticides for dogs and cats, pet owners and veterinarians must be provided with evidence to support their decision to select a product to control fleas. To compare the efficacy of three commercially available products against companion animal fleas, a trial was conducted on naturally-infested dogs in order to validate their pulicidal activity. Thirty-two flea-infested dogs with fleas were divided into 4 groups (n = 8) for each treatment. Group 1 received one pipette of permethrin as a spot-on dose of 650 mg/ml. The second group received 9.7% fipronil as a spot-on formulation. Group 3 was treated with a spot-on formulation of permethrin 7.40% plus piperonyl butoxide at 7.40%. Group 4 remained as the untreated control. Fleas of all experimental dogs were examined and counted on days 0, 3, 7, 14, 21 and 28 to determine the percentage of flea reduction. Results showed a 100% efficacy for all tested products. Identified species were: Ctenocephalides felis (75.7%), Ctenocephalides canis (15.9%) and Pulex irritans (9.5%). Based on these results, it was concluded that the three anti-flea products evaluated under the conditions of this study, produced an excellent efficacy as from the third day after treatment.

The use of phoxim and bendiocarb for control of fleas in farmed mink (Mustela vison)

BackgroundFleas (Ceratophyllus sciurorum) are common on farmed mink in Denmark. When present, the fleas have a negative impact on the health of the farmed mink and are of nuisance for farm staff. Severe infestations of fleas cause anemia, poor growth and may result in death of mink kits. Changed behavior of the dams is also observed. Further it has been demonstrated that the fleas are vectors of Aleutian disease virus. Flea control is based on use of a few insecticides and resistance has been reported against permethrin. There is thus a need for new flea control products. In this blinded, randomized clinical trial according to GCP standard, phoxim spray and bendiocarb powder for flea control on mink farms were investigated.ResultsBoth the phoxim spray solution and bendiocarb powder were found to be efficient for the control of C. sciurorum fleas on farmed mink. Phoxim treatments reduced the number of fleas by 98.4% and the bendiocarb treatments reduced the number of fleas by 99.0% in the mink nest boxes when compared to counts in controls. No clinical signs were observed post treatment.ConclusionsThe study demonstrated that phoxim sprayed on the animals and the use of bendiocarb powder in the nest box material were highly efficient for the control of the C. sciurorum fleas on farmed mink. Both products were safe to use at the recommended dose rate. Both compounds are recommended to be integrated in a new farm management plan suggested here.

Update on flea and tick associated diseases of cats

There are multiple vector-borne diseases in cats, the most prominent being those transmitted by mosquitos, sand flies, fleas, and ticks. Many of the agents vectored by fleas or ticks have been grown or amplified from blood or have induced antibodies in the serum of normal cats or those with clinical signs like fever and will be the focus of this manuscript. As high as 80% of fleas collected from cats contain at least one organism that could induce illness in cats or people. Anaplasma phagocytophilum, Bartonella spp., Borrelia spp., Ehrlichia spp., hemoplasmas, and Rickettsia spp. infect cats and can be associated with clinical illness. Anaplasma phagocytophilum and B. burgdorferi are transmitted by Ixodes spp., Ehrlichia spp. and A. platys are transmitted by Rhipicephalus sanguineus. Fleas vector Bartonella spp., hemoplasmas, and R. felis. Recently, R. typhus was detected in cats in Spain. Lethargy and fever are common findings in cats with flea and tick borne diseases. Hemoplasmas are associated with hemolytic anemia. Moderate thrombocytopenia is associated with the tick-vectored agents. Polymerase chain reaction assays performed on blood collected in the acute phase of infection can be used to prove presence of the organisms. Doxycycline at 5 mg/kg, PO, twice daily or 10 mg/kg, PO, daily can be effective for resolving the clinical signs. If doxycycline is ineffective or not tolerated, fluoroquinolones can be effective for treatment of clinical illness associated with Bartonella spp., hemoplasmas, and Rickettsia spp. Use of flea and tick control products is effective for blocking transmission of many of the agents.

Itching for change: Embracing modern flea and tick product development

The development and regulatory approval of ectoparasiticides, including flea and tick control products, involves decades-old methods and the use of large numbers of animals to evaluate toxicity and efficacy. Animals also are used to rear (breed and feed) fleas and ticks for later use in testing. Non-animal methods for regulatory-required testing and rearing currently exist and, with further development, others could soon become available. Here we provide an overview of the state-of-the-science of non-animal methods for rearing and regulatory-required efficacy testing of flea and tick control products. Several remaining challenges as well as recommendations on the steps needed to replace animals in the evaluation of these products are discussed.

An open, self-controlled study on the efficacy of topical indoxacarb for the treatment of dermatitis and pruritus associated with flea infestation in client-owned cats suffering from flea-induced allergic dermatitis

Summary Flea-induced allergic dermatitis (FIAD) is frequent in cats. Despite widespread availability of flea-control products, little is known about the speed of resolution of FIAD clinical signs after treatment of affected cats with only an effective flea adulticide. To evaluate the resolution of clinical signs and pruritus in cats suffering from FIAD, twelve cats with pre-existing flea-induced allergic dermatitis, which presented to a dermatology referral service, were enrolled in an open-label non-controlled study in which all cats were treated two times with topical indoxacarb at 4 week intervals, with no concomitant treatments and followed for 56 days. Eleven cats completed the study. Mean clinical scores (SCORing of Feline Allergic Dermatitis) were reduced by 52% at week 4 and 75% at week 8. Mean owner assessed pruritus scores were reduced by 57% at week 4 and 79% at week 8. A statistically significant improvement in pruritus was observed 14 days after the initial treatment. Mean flea counts were reduced by 100% at week 4 and week 8. Topical indoxacarb treatment applied every 4 weeks without any concomitant antipruritic therapy eliminated the flea infestation, improved the clinical signs of FIAD and reduced the owner perception of pruritus in all cats.

Evaluation of hair loss in cats occurring after treatment with a topical flea control product

A formulation containing 39.6% spinetoram resulted in a higher than anticipated number of reports of alopecia at the site of application in the first months following commercial product launch. To determine the cause of the alopecia using histopathology, including assessment for inflammation, follicular findings of physical trauma (plucking/pulling behaviour) and changes in follicular cycling. Twenty-four flea-free, male and female adult domestic short hair cats within a private research colony. Cats were treated with a single application of 39.6% spinetoram on day 0; personnel were not blinded. Observations of the skin and hair coat began immediately and were repeated at 30 min and 1, 2, 3, 4, 6, 8 and 12 h post-application and then on subsequent days at the same time as initial dosing and at 2, 4, 6, 8 and 12 h after that time, until day 5. If hair thinning or loss was observed, a skin biopsy sample was collected. Two cats not exhibiting abnormalities were biopsied on day 6. Thirty-eight per cent of cats (nine of 24) developed hair thinning and alopecia of sufficient severity within 78 h post-application of the product to warrant skin biopsy. Abnormalities in the skin were limited to the application site and were consistent with physical trauma (pulling or plucking) to the hair. Microscopic changes in the hair follicles of affected cats were consistent with self-induced trauma or barbering behaviour. All changes were reversible and paralleled findings associated with well-established, topical flea control products.

Assessment of owner-administered monthly treatments with oral spinosad or topical spot-on fipronil/(S)-methoprene in controlling fleas and associated pruritus in dogs

Monitoring of the performance of flea control products under conditions of natural challenge is valuable in assessing continued effectiveness and determining the ongoing relevance of laboratory studies. A multi-clinic, investigator-blinded study was undertaken in client-owned dogs to investigate and compare the flea control provided by 3 consecutive monthly treatments of oral spinosad (SPN) or fipronil/(S)-methoprene topical (FSM) spot-on. The first household dog meeting enrollment criteria and with at least 10 fleas (whole-body flea count) served as the index dog in a household against which primary objectives were set. Stratification was based on pruritus scores at the enrollment visit and on single or multiple pet household. Index pets were randomized to treatment with either SPN or FSM, dispensed on day 0 for at-home administration by owners. All other household dogs and cats, maximum 4 pets per household, were dispensed the same treatment as the index dog (spinetoram was dispensed for cats in SPN households). Subsequent treatments were dispensed when index dogs were returned for whole-body flea counts and pruritus-scoring at visits on days 30 and 60, with final assessments on day 90 (±5 days on each occasion). Primary endpoints were the number of flea-free index dogs in each group one month after the final treatment, the reduction in owner-reported pruritus, and the reduction from baseline mean flea counts. One hundred twenty eight index dogs were enrolled (65 in the SPN arm; 63 in the FSM arm) at 10 clinics in FL (6), NC (2), LA (1), and TX (1). On day 0, geometric mean flea counts were 57.7 (range: 10–1469) and 44.8 (10–717) for the SPN and FSM groups, respectively. On Day 90, 55 of 58 (95%) and 21 of 55 (38%) index dogs completing the study were flea-free in SPN and FSM groups, respectively; mean SPN pruritus scores declined to 0.92 (6.67 on day 0), and to 3.83 (6.33 on day 0) for FSM; geometric mean flea counts (% control) were 0.08 (99.9%) and 5.19 (88.4%), for SPN and FSM groups, respectively. Between-treatment differences were highly statistically significant (p<0.0001). In conclusion, SPN provided reliable flea control in client-owned dogs, regardless of challenge level.

Prevalence of Bartonella species, hemoplasmas, and Rickettsia felis DNA in blood and fleas of cats in Bangkok, Thailand

Flea infestations are common in Thailand, but little is known about the flea-borne infections. Fifty flea pools and 153 blood samples were collected from client-owned cats between June and August 2009 from veterinary hospitals in Bangkok, Thailand. Total DNA was extracted from all samples, and then assessed by conventional PCR assays. The prevalence rates of Bartonella spp. in blood and flea samples were 17% and 32%, respectively, with DNA of Bartonella henselae and Bartonella clarridgeiae being amplified most commonly. Bartonella koehlerae DNA was amplified for the first time in Thailand. Hemoplasma DNA was amplified from 23% and 34% of blood samples and flea pools, respectively, with ‘Candidatus Mycoplasma haemominutum’ and Mycoplasma haemofelis being detected most frequently. All samples were negative for Rickettsia felis. Prevalence rate of B. henselae DNA was increased 6.9 times in cats with flea infestation. Cats administered flea control products were 4.2 times less likely to be Bartonella-infected.

Therapy of flea allergy dermatitis (FAD) in dogs and cats: Part 2

This article explores the different formulations of flea-control products available for use on animals with flea-allergy dermatitis, and in the environment. It also considers the importance of constructing a practical flea control programme based on the particular circumstances of the patient, in-contact animals, owner and surrounding environment. Possible reasons for flea control failure are outlined.

Therapy of flea allergy dermatitis (FAD) in dogs and cats: Part 1

This article considers the aims of therapy in the patient with flea allergy dermatitis (FAD), and the range of flea-control products, available for use on the animal and in the environment. Removal of the source of antigenic challenge, the flea, from the patient and the patient's environment should be the ultimate aim of therapy. Whilst this is being achieved, symptomatic antipruritic therapy may be indicated to alleviate clinical signs and reduce discomfort. Insecticides are usually required on the animal and in the surrounding environment. Selection of flea-control products is influenced by the biological and therapeutic characteristics of each insecticide and needs to be customised to individual circumstances.

Cutaneous bacillary angiomatosis in renal transplant recipients: report of three new cases and literature review

Bacillary angiomatosis (BA) is a rare vasculoproliferative disorder due to Bartonella henselae (BH) or Bartonella quintana. It can involve many organs, including the skin, and has been mainly reported in patients with acquired immunodeficiency syndrome. In organ transplant recipients (OTR), this disorder remains misdiagnosed and therapeutic guidelines are nonexistent. We report 3 cases of BA with skin involvement in OTR and review similar cases from the literature. BA manifests on the skin with violaceous lesions mimicking Kaposi sarcoma, and is associated with fever, lymphadenopathy, and liver, spleen, or lung nodules. Bartonellosis infections in OTR are due to BH, the agent causing cat-scratch disease (CSD), but BA comprises histologically a prominent vascular proliferation, which is usually lacking in CSD. Cultures and serologic tests are poorly reliable for the diagnosis, which relies on demonstration of BH within the lesions. A history of cat exposure exists in most cases and pediatric OTR are at higher risk. Prevention consists of regular use of a flea-control product in cats and prompt cleaning of scratches. Our cases highlight several original features of this rare condition, which could potentially improve the management of BA in OTR.

Household chemical exposures and the risk of canine malignant lymphoma, a model for human non-Hodgkin’s lymphoma

BackgroundEpidemiologic studies of companion animals offer an important opportunity to identify risk factors for cancers in animals and humans. Canine malignant lymphoma (CML) has been established as a model for non-Hodgkin’s lymphoma (NHL). Previous studies have suggested that exposure to environmental chemicals may relate to development of CML. MethodsWe assessed the relation of exposure to flea and tick control products and lawn-care products and risk of CML in a case–control study of dogs presented to a tertiary-care veterinary hospital (2000–2006). Cases were 263 dogs with biopsy-confirmed CML. Controls included 240 dogs with benign tumors and 230 dogs undergoing surgeries unrelated to cancer. Dog owners completed a 10-page questionnaire measuring demographic, environmental, and medical factors. ResultsAfter adjustment for age, weight, and other factors, use of specific lawn care products was associated with greater risk of CML. Specifically, the use of professionally applied pesticides was associated with a significant 70% higher risk of CML (odds ratio(OR)=1.7; 95% confidence interval (CI)=1.1–2.7). Risk was also higher in those reporting use of self-applied insect growth regulators (OR=2.7; 95% CI=1.1–6.8). The use of flea and tick control products was unrelated to risk of CML. ConclusionsResults suggest that use of some lawn care chemicals may increase the risk of CML. Additional analyses are needed to evaluate whether specific chemicals in these products may be related to risk of CML, and perhaps to human NHL as well.

Field evaluation of imidacloprid as a systemic approach to flea control in black-tailed prairie dogs, Cynomys ludovicianus

Epizootic outbreaks of sylvatic plague have dramatically influenced prairie dog (Cynomys sp.) populations across North America. While a great deal of debate surrounds the cause and persistence of plague, flea control can stop the spread of plague epizootic outbreaks and even increase prairie dog survival under non-epizootic conditions. We investigated a newly-developed imidacloprid-treated grain bait that could potentially reduce flea infestations and mitigate the effects of plague on black-tailed prairie dogs (C. ludovicianus). We used a study design involving randomly assigned experimental and control study plots to assess the effectiveness of the systemic flea control product. We observed a significant difference in flea prevalence and abundance between experimental and control sites on three of the four sites treated with a single application of imidacloprid-treated grain bait for up to 90 days post-treatment. We observed an even greater reduction in flea infestations following the double application of treatment bait on two of three additional experimental sites. While we were unable to reduce flea infestations to the extent reported for more commonly used topical insecticides containing deltamethrin, imidacloprid might still be effective at reducing the risk of plague and halting epizootics. In addition, this systemic product can be more rapidly applied than topical insecticides, providing managers with a tool to quickly reduce flea infestations. Future research is needed to evaluate the effectiveness of different application timing and rates, the utility of the product in limiting plague, and the potential effects on non-target species that might also consume the treated bait.

Prevalence of Bartonella species, haemoplasmas and Toxoplasma gondii in cats in Scotland

The objective of this study was to determine the prevalence rates for select infectious agents of cats presented to the Royal (Dick) School of Veterinary Studies at the University of Edinburgh, Scotland. Whole blood, serum, and oral mucosal and nail bed swabs were collected. While Ehrlichia species, Anaplasma species or Rickettsia felis DNA were not amplified from any cat, 44.2% of the cats had evidence of infection or exposure to either a Bartonella species (15.3% were seropositive and 5.8% polymerase chain reaction (PCR) positive), a haemoplasma (28.6% PCR positive), and/or Toxoplasma gondii (19.2% seropositive). No Bartonella species DNA was amplified from the nail or oral mucosal swabs despite a 5.8% amplification rate from the blood samples. This finding likely reflects the absence of Ctenocephalides felis infection from our study population, as this organism is a key component for Bartonella species translocation in cats. The results from this study support the use of flea control products to lessen exposure of cats (and people) to Bartonella species and support discouraging the feeding of raw meat to cats and preventing them from hunting to lessen T gondii infection.